
#### CARB-X: Accelerating Innovation

Erin M Duffy, PhD R&D Chief emduffy@bu.edu

FDA-IDSA-NIH-Pew Public Workshop, November 18, 2019

# CARB-X Combating Antibiotic Resistant Bacteria



#### A global partnership accelerating science to fight drug resistant bacteria

Combating Antibiotic Resistant Bacteria

CARB-X

**FUNDERS** 



wellcome

National Institute of Allergy and Infectious Diseases



Federal Ministry of Education and Research

**ALLIANCE PARTNER** 

BASEL

AREA.

SWISS

for Infection Research



**ACCELERATORS** 

















# CARB-X is investing > \$500 million in 2016-2021\*

# Supporting R&D from around the world to address the most serious drug-resistant bacteria


- 50 funded projects thus far, globally
- >\$150MM obligated to date
- >15 approved projects not yet announced
- Non-dilutive funding and accelerator support for the early development of antibiotics, rapid diagnostics, and vaccines




# What CARB-X funds today

- Discovery and early development projects that address serious bacterial threats
  - Traditional and non-traditional therapeutics
  - prevention such as vaccines, microbiome, antibodies
  - rapid diagnostics (pathogen ID/AST)

Projects must target specific bacteria on the <u>Antibiotic</u> <u>Resistance Threats List</u> issued by the Centers for Disease Control and Prevention (CDC) in 2013 or on the <u>Priority</u> <u>Bacterial Pathogens list</u> published by the World Health Organization (WHO) in 2017




#### CARB-X supports Discovery and early Development



NB - scope definitions will be refined prior to the opening of each specific funding round


### Portfolio: direct-acting Tx



#### Portfolio: non-traditional




#### Portfolio: vaccines and immunotherapies




#### Portfolio: Dx

T2 Biosystems Talis HelixBind Proteus Specific Dx

### Portfolio view at project initiation



# Significant advances, including 🞓



## 2019: Four Funding Rounds



- Funding Round 1 Non-traditional approaches now closed
  Open for applications: June 3 June 10, 2001
- Funding Round 2 Vaccines and biotherapeutics
   Open for applications: July 8 July 15, 2010.  $\bullet$ now closed
- Funding Round 3 Diagnostics  $\bullet$ 
  - Open for applications: August 12 August 19, 2019, 5 PM ET
- open for business! • Funding Round 4 – Direct-acting small molecule
  - Open for applications: November 12 November 19, 2019, 5 PM ET

#### The only way to apply

Applicants must complete and submit the online Expression of interest form at <u>https://carb-x.org/apply</u> during the periods specified for each round. The online application tool will be functional only during these periods.

# CARB-X is more than funding (1) Scientific and Business Expertise and Support



saving products to fight drug-resistant bacteria

# CARB-X is more than funding (2) Scientific and Business Expertise and Support

#### CARB-X Support Team/Lead for each company

- Accelerator support tailored to company needs
- Specialized knowhow in antibacterial drug development, diagnostics, vaccines, business and legal strategy, regulatory affairs and other areas essential to product development
- No cost to product developers
- Streamlined access to NIAID preclinical services
- Benefits of CARB-X ecosystem







#### CARB-X is more than funding (3) Internal R&D: cross-portfolio challenges & opportunities

- Several consistent threads have emerged across projects in CARB-X portfolio
  - Opportunity to establish best practices and guide developers
  - Enables a better baseline understanding of pipeline
  - Unique opportunity to lead the field in certain development areas
  - Provide data as "a collective" to leverage resources

#### CARB-X is more than funding (4) Internal R&D: cross-portfolio challenges & opportunities

- Nephrotoxicity models and translation to clinic
- Translation of preclinical data to clinic for cystic fibrosis programs
- Gonorrhea models and regulatory development
- Anti-virulence animal models and regulatory path
- Examination of global pre-existing resistance trends
- Toolbox to assess lack of antibacterial activity, particularly due to influx and efflux, and to afford SAR to enhance activity
- Best practices PK/PD to bolster product dossier
- Ways to leverage Dx across portfolio

### Shameless plug: we're building our R&D team!



- What? Alliance Directors & Managers
- Areas?
  - Small-molecule therapeutics
  - Large-molecule therapeutics
  - Prevention
  - Diagnostics
- More info?
  - https://carb-x.org/about/careers/



